The Quest for Longevity
The desire to conquer death has been a recurring theme in pop culture, seen in works like “The Picture of Dorian Gray,” “Death Becomes Her,” and “Harry Potter and the Philosopher’s Stone.” However, recent years have seen this dream shift from fiction to reality, thanks to over $5 billion in investments from notable figures like Peter Thiel, Jeff Bezos, and Sam Altman.
This wealthy group is pursuing the secrets of aging at the molecular level, while others are zeroing in on specific age-related diseases, such as Parkinson’s. Among various ventures, Singapore-based Immortal Dragons stands out with its audacious mission of “making death optional.”
Introducing Immortal Dragons
Boyang Wang, the 34-year-old CEO of Immortal Dragons, has been captivated by longevity for years. His interest was sparked by a personal health scare involving anaphylactic shock, which made him reflect on preventive medicine. This incident led him to envision a world where allergies could be addressed before they even manifest.
In December 2023, Wang launched Immortal Dragons, bolstered by approximately $4 million from friends and family, alongside $36 million of his own funds. He aims to invest in ambitious projects that hold potential for both significant risks and rewards.
One notable company in Immortal Dragons’ portfolio is Frontier Bio, which specializes in 3D biofabrication technology to create organs without relying on donors, potentially alleviating long transplant waitlists in the U.S.
Additionally, the fund has invested $500,000 in a project focused on creating ape-like mammals with underdeveloped nervous systems. This approach raises ethical questions about using non-sentient beings for research instead of conscious animals, which some argue could be a more humane alternative.
Immortal Dragons also backs Unlimited Bio, currently running clinical trials on innovative treatments, including gene therapies aimed at reducing age-related muscle deterioration. Meanwhile, the organization has been active in advocacy, successfully pushing for New Hampshire’s “Right to Try” law, allowing terminally ill patients to access experimental treatments.
Combating Disease
The fund also channels resources into projects that stem from personal passions. Take Andy Tsai, who witnessed his grandfather suffer from Alzheimer’s and Parkinson’s. This experience profoundly impacted him, leading him to question why some individuals can lead longer, healthier lives than others.
Now a doctoral student in neurology at Stanford, Tsai’s pioneering research has received backing through a four-year partnership with Immortal Dragons.
The Nuances of Longevity
The concept of longevity is not straightforward; its meaning varies significantly from person to person. While Immortal Dragons aspires to explore eternal life, Tsai defines longevity more as the ability to maintain optimal health over time, thus minimizing unhealthy years.
While advocates believe longevity research has universal implications, skeptics might view it as a high-end pursuit that overlooks pressing issues faced by many, like financial insecurity. With a significant portion of the population struggling with healthcare costs, the idea can seem disconnected.
Eventually, as Medicare coverage expands, a substantial part of healthcare spending will go towards elderly care, exemplifying how neglected health can burden families and the healthcare system alike.
Despite the association of wealth with longevity endeavors, Tsai argues that the findings from such research can have broad social benefits. Wealth does not shield anyone from the harsh realities of diseases like Alzheimer’s and Parkinson’s.
His ongoing research, focused on longevity-associated genetic mutations found in centenarians, aims to replicate these traits in younger populations to fend off age-related ailments.
Ultimately, whether one finds this pursuit of longevity worthwhile or not, it raises essential considerations about the health of aging demographics and the implications for future generations. A healthier elderly population could reduce the demand for caretakers and nursing homes, thereby easing the strain on societal resources.
“We believe this research has the potential to help everyone, particularly individuals aged 40 to 60,” Tsai remarked. “They’re still in good health, and our current focus is to intervene while they’re well to keep them that way.”
